This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | MicrobiomeTrials
← Back to trials NCT06706674
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-12-06Est. Completion: 2027-06-21
Enrollment target: 160 participantsLocations Pillar Clinical Research, LLC, Little Rock, Arkansas, United States University Of California - Davis, Sacramento, California, United States California Neuroscience Research, Sherman Oaks, California, United States Yale University School Of Medicine, New Haven, Connecticut, United States United Research Institute, Hialeah, Florida, United States Advanced Research Institute of Miami, Homestead, Florida, United States Vital Care Research, Miami, Florida, United States Care Research Center Inc, Miami, Florida, United States Blue Medical Research, Miami, Florida, United States AP Medical Research, Miami, Florida, United States GTL Medical and Research Group, Miami, Florida, United States New Med Research Inc, Miami Gardens, Florida, United States Riveldi Biomedical Research, Miami Lakes, Florida, United States APG Research LLC, Orlando, Florida, United States Orlando Psychiatric Associates, Orlando, Florida, United States Clinical Research Center of Florida, Pompano Beach, Florida, United States Other microbiome trials you might be interested in Autism Autism Spectrum Disorder Autism Disorder
This is a double-blind, randomised, placebo-controlled study investigating the efficacy of a full-spectrum medicinal can…
Clayton, Australia Est. completion Jul 1, 2029
Autism Spectrum Disorder Challenging Behaviour Aggression Severe Disruptive Behaviour Disorders Self-injury
The goal of this clinical trial is to learn if propranolol can help reduce challenging behaviors associated with Autism …
University of South Florida Rothman Center of Neuropsychiatry, St. Petersburg, Florida, United States
Advanced Discovery Research, Atlanta, Georgia, United States
Salveo Integrative Health Inc, Lawrenceville, Georgia, United States
EmVenio Research at Chicago, Chicago, Illinois, United States
Baber Research Group, Naperville, Illinois, United States
Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States
Neurobehavioral Medicine Group, Bloomfield Hills, Michigan, United States
Alivation Research LLC, Lincoln, Nebraska, United States
NYU Child Study Center, New York, New York, United States
Nathan Kline Institute, Orangeburg, New York, United States
Richmond Behavioral Associates, Staten Island, New York, United States
Advantage Clinical Trials, The Bronx, New York, United States
Quest Therapeutics of Avon Lake, Avon Lake, Ohio, United States
SP Research, PLLC (dba Rivus Wellness & Research Institute), Oklahoma City, Oklahoma, United States
Sooner Clinical Research, Oklahoma City, Oklahoma, United States
Medical University of South Carolina, Charleston, South Carolina, United States
BioBehavioral Research of Austin PC, Austin, Texas, United States
Texas Research Group, Coppell, Texas, United States
Future Search Trials of Dallas, Dallas, Texas, United States
North Texas Clinical Trials, Fort Worth, Texas, United States
Red Oak Psychiatry Associates, Houston, Texas, United States
Virginia Commonwealth University, Richmond, Virginia, United States
Core Clinical Research, Everett, Washington, United States Staten Island, United States Est. completion Nov 2028
Sleep Disturbance Autism Spectrum Disorder
As many as 78% of children with autism spectrum disorder (ASD) have significant sleep disturbance compared to 20% of chi…
Cleveland, United States Completed Dec 9, 2026